People · Operator
Named in public records as an officer, director or promoter · active 2018–2025 · Other, Other Health Care, Other Technology, Biotech / Pharma, Healthtech, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Opentrons Labworks Inc. | — | Other | Series D+ | $303.4M | $156.0M | 2025 |
| Hello Heart Inc. | — | Other Health Care | Series C | $127.0M | $1.0B | 2019 |
| Vivodyne, Inc. | — | Other Technology | Series C | $79.7M | $606.1M | 2025 |
| KRNL, Inc. | — | Other | Series C | $58.2M | $45.8M | 2023 |
| Colorescience Inc | — | Other Health Care | Series B | $51.2M | $66.5M | 2018 |
| Prellis Biologics, Inc | — | Biotech / Pharma | Series B | $47.3M | $276.9M | 2021 |
| Gather Health Primary Care, Inc. | — | Healthtech | Series B | $37.5M | $105.5M | 2024 |
| Fountain Therapeutics, Inc. | — | Biotechnology | Series B | $26.9M | $348.5M | 2021 |
| Faeth Therapeutics, Inc. | — | Biotechnology | Series B | $24.4M | $109.3M | 2025 |
| Artrendex, Inc. | — | Other Technology | Seed | $2.4M | $81.8M | 2018 |
Alex Morgan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alex Morgan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Marks | 1 | 20 |
| David F Hale | 1 | 16 |
| Jason Johnson | 1 | 13 |
| Rohit Sharma | 1 | 10 |
| Bruce Armstrong | 1 | 10 |
| Adele Oliva | 1 | 9 |
| SVEN STROHBAND | 1 | 8 |
| Somesh Dash | 1 | 8 |
| Eric Hippeau | 1 | 8 |
| Josh Baltzell | 1 | 7 |
| Brian H. Dovey | 1 | 7 |
| Alon Krashinsky | 1 | 6 |
| William Greene | 1 | 6 |
| Ron Shah | 1 | 6 |
| Joshua J. Baltzell | 1 | 5 |
| Riaz Valani | 1 | 5 |
| John Malloy | 1 | 5 |
| BRYAN JOHNSON | 1 | 4 |
| Prateesh Maheshwari | 1 | 4 |
| James H. Cavanaugh, Ph.D. | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.